Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Size Shifted, And What Is the Outlook Through 2034?
The market size for treatment of metabolic dysfunction-associated steatohepatitis (mash) has witnessed formidable expansion in the recent past. Expected to rise from $2 billion in 2024 to $2.59 billion in 2025, it showcases a compound annual growth rate (CAGR) of 29.7%. The growth observed in the previous period is due in part to an increase in cases of non-alcoholic steatohepatitis, changes in dietary customs leaning towards processed foods, sedentary living patterns, and a growing prevalence of metabolic issues.
Expectations are high for the metabolic dysfunction-associated steatohepatitis (mash) treatment market to experience significant growth in the coming years. Specialists project that it will expand to $7.29 billion in 2029, demonstrating a compound annual growth rate (CAGR) of 29.5%. Factors contributing to this growth in the prediction period include the rising occurrence of obesity and related health conditions, early medical intervention, reimbursement processes, insurance plans, and increasing awareness about liver disorders. Key trends anticipated during the forecast period involve enhancements in technology, developments in the pipeline, strategic alliances and collaborations, individualized treatment and precision therapeutics, and investments in clinical studies and research.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20876&type=smp
What External and Internal Drivers Are Contributing to the Growth of theMetabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
The metabolic dysfunction-associated steatohepatitis (MASH) treatment market is projected to expand due to the escalating occurrence of obesity. Obesity, defined as an excessive build-up of body fat negatively impacting health and marked by a body mass index (BMI) of 30 or more, is on the rise globally. Factors such as inactive lifestyles, poor eating habits, and metabolic risk aspects contribute to obesity. Addressing insulin resistance, lowering liver fat, and enhancing metabolic health through lifestyle modifications and specific therapies constitute the focus of MASH treatment in obese patients. For example, the Switzerland-based World Heart Foundation, a global non-governmental cardiovascular community, revealed in March 2023 that approximately 2.3 billion children and adults around the world are overweight or obese. With the current trend, this figure is expected to climb up to 2.7 billion by 2025. Hence, the growing occurrence of obesity is fueling the advancement in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market.
What Segment Types Define the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Structure?
The metabolic dysfunction-associated steatohepatitis (mash) treatmentmarket covered in this report is segmented –
1) By Treatment: By Drug; By Therapy
2) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-User
3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
Subsegments:
1) By Drug: Antifibrotic Agents; Antidiabetic Drugs; Lipid-Lowering Agents; Vitamin E; Obeticholic Acid (OCA); GLP-1 Agonists; Other Drugs (Anti-Inflammatory Agents)
2) By Therapy: Pharmacotherapy; Lifestyle Modifications (Dietary Changes, Exercise); Bariatric Surgery; Liver Transplantation
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=20876&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
North America was the largest region in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Long-Term Trends Are Transforming the Competitive Landscape of the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
Leading corporations in the metabolic dysfunction-associated steatohepatitis (MASH) treatment field, are making strides towards devising innovative products like liver fibrosis therapy solutions. These solutions cater to patients struggling with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to severe liver fibrosis. The emphasis of liver fibrosis therapy solutions is on dealing with the root causes of liver injury through changes in lifestyle, application of antiviral drugs, and the advent of antifibrotic treatments with the aim to arrest or reverse the advancement of fibrosis and enhance liver performance. For example, in March 2024, an announcement was made by Madrigal Pharmaceuticals, Inc., a biopharmaceutical organization based in the US, about the FDA’s approval of Rezdiffra (resmetirom), the inaugural treatment for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to severe liver fibrosis. Rezdiffra is a daily tablet which exhibited effectiveness in countering MASH without aggravating fibrosis and ameliorating liver fibrosis in phase 3 clinical studies. This pioneering solution presents a non-invasive treatment option, removing the requirement for liver biopsies, and significantly augmenting patient access and results in the administration of fatty liver disease.
View the full report here:
What Is the Definition of the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
Metabolic dysfunction-associated steatohepatitis (MASH) treatment refers to medical and lifestyle interventions aimed at addressing inflammation and liver damage caused by fat accumulation in the liver associated with metabolic dysfunctions like obesity, diabetes, and insulin resistance, focusing on improving liver health and metabolic outcomes.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20876
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model